PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.43%
Positive revenue growth while 3141.T is negative. John Neff might see a notable competitive edge here.
-0.51%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
51.44%
Positive EBIT growth while 3141.T is negative. John Neff might see a substantial edge in operational management.
1.06%
Positive operating income growth while 3141.T is negative. John Neff might view this as a competitive edge in operations.
52.44%
Positive net income growth while 3141.T is negative. John Neff might see a big relative performance advantage.
52.44%
Positive EPS growth while 3141.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
52.44%
Positive diluted EPS growth while 3141.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.
0.00%
Slight or no buybacks while 3141.T is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
0.00%
Slight or no buyback while 3141.T is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
52.55%
10Y revenue/share CAGR under 50% of 3141.T's 159.91%. Michael Burry would suspect a lasting competitive disadvantage.
59.61%
5Y revenue/share CAGR similar to 3141.T's 60.01%. Walter Schloss might see both companies benefiting from the same mid-term trends.
26.86%
3Y revenue/share CAGR at 75-90% of 3141.T's 34.26%. Bill Ackman would expect new product strategies to close the gap.
100.00%
10Y OCF/share CAGR in line with 3141.T's 100.00%. Walter Schloss would see both as similarly efficient over the decade.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
222.32%
Net income/share CAGR at 50-75% of 3141.T's 423.51%. Martin Whitman might question if the firm’s product or cost base lags behind.
177.62%
5Y net income/share CAGR above 1.5x 3141.T's 106.25%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
107.89%
3Y net income/share CAGR above 1.5x 3141.T's 28.60%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
194.93%
10Y equity/share CAGR at 50-75% of 3141.T's 278.29%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
125.91%
5Y equity/share CAGR above 1.5x 3141.T's 71.50%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
59.94%
3Y equity/share CAGR above 1.5x 3141.T's 37.82%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative near-term dividend growth while 3141.T invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
10.26%
AR growth well above 3141.T's 3.75%. Michael Burry fears inflated revenue or higher default risk in the near future.
-1.27%
Inventory is declining while 3141.T stands at 10.49%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
1.24%
Asset growth at 75-90% of 3141.T's 1.53%. Bill Ackman suggests reviewing opportunities to match or surpass the competitor's asset expansion if profitable.
4.71%
Positive BV/share change while 3141.T is negative. John Neff sees a clear edge over a competitor losing equity.
-5.89%
We’re deleveraging while 3141.T stands at 14.58%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-0.94%
We cut SG&A while 3141.T invests at 3.61%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.